Alcon Inc. Ordinary Shares (NY:ALC)

63.76 -0.18 (-0.28%)

Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alcon Inc. Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Star Surgical Shines as U.S. Outlook Improves for 2024

April 16, 2024

STAAR Surgical is increasing its outlook and guidance as demand for its signature IOL procedure increases with an aging population

Via MarketBeat

Alcon Publishes Agenda for 2024 Annual General Meeting

April 07, 2024

From Alcon Inc. Investors

Via Business Wire

Alcon Inc. (NYSE: ALC) Records 52-Week High Tuesday Morning

March 12, 2024

Via Investor Brand Network

Vivity, the World’s Leading EDOF IOL, Reaches One Million Milestone

March 06, 2024

From Alcon Inc. Corporate

Via Business Wire

What 6 Analyst Ratings Have To Say About Alcon ↗

December 04, 2023

Via Benzinga

The Latest Analyst Ratings for Alcon ↗

November 16, 2023

Via Benzinga

Why Medical Device Company Alcon Shares Are Sliding Today ↗

November 15, 2023

Alcon Inc (NYSE: ALC) shares are trading lower by around 5%

Via Benzinga

Alcon's Broad Portfolio Delivers Robust Sales and Earnings Growth in FY 2023

February 27, 2024

From Alcon Inc. Investors

Via Business Wire

Earnings Preview: What To Expect To When Eye Health Company Bausch + Lomb Reports Q4 Performance Later This Month ↗

February 09, 2024

"Bausch + Lomb's Q4 & FY 2023 results on Feb 21, 2024. Expecting $1.107 billion in sales, $0.17 EPS. RBC Capital predicts $1.159 billion revenue. Insights on Miebo launch and enhanced EBITDA margins...

Via Benzinga

Buy This Ophthalmology Stock But Sell This One, Says Bernstein Analyst: 'Innovation Is Key' ↗

January 23, 2024

Innovation and digitalization have been in focus among ophthalmology majors.

Via Benzinga

Good News For Dry Eye Disease Patients: Eye Care Focused Alcon's Treatment Shows Encouraging Benefit In Late-Stage Trials ↗

January 10, 2024

Alcon (NYSE: ALC) released topline results from the two Phase 3 trials (COMET-2 and COMET-3) evaluating the efficacy and safety of AR-15512, a candidate treatment for the signs and symptoms of

Via Benzinga

Where Alcon Stands With Analysts ↗

September 08, 2023

Via Benzinga

Alcon Inc. (NYSE: ALC) Highlighted for Surprising Price Action

August 17, 2023

Via Investor Brand Network

Where Alcon Stands With Analysts ↗

August 17, 2023

Via Benzinga

Alcon Announces Positive Topline Results From Phase 3 COMET Trials of AR-15512, a Novel Topical Drug Candidate for Dry Eye

January 09, 2024

From Alcon Inc. Investors

Via Business Wire

Lifecore Biomedical Expands Relationship with Existing Long-Term Customer Through a Series of Commercial Arrangements

January 05, 2024

From Lifecore Biomedical, Inc.

Via GlobeNewswire

Alcon to Present at 2024 Annual J.P. Morgan Healthcare Conference

December 27, 2023

From Alcon Inc. Investors

Via Business Wire

Intel To Rally Over 23%? Here Are 10 Top Analyst Forecasts For Thursday ↗

November 16, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Why Shapeways Holdings Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

November 15, 2023

Shares of Shapeways Holdings, Inc. (NASDAQ: SHPW) tumbled during Wednesday’s session following downbeat results.

Via Benzinga

US Stocks On Track To Build On Gains As Traders Await A Batch Of Data; Can Market Resist Profit Taking? ↗

November 15, 2023

U.S. stocks could build on the momentum they picked up on Tuesday following the release of benign inflation data. Traders get to digest another batch of economic data on producer price inflation,...

Via Benzinga

Topics Economy

Varex Imaging Reports Weak Sales, Joins Alcon, XPeng And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

November 15, 2023

U.S. stock futures traded higher this morning on Wednesday, with the Dow Jones futures gaining more than 90 points this morning.

Via Benzinga

Topics Stocks

Alcon Reports Third Quarter 2023 Results

November 14, 2023

From Alcon Inc. Investors

Via Business Wire

Alcon Gears Up For Q3 Print; Here's A Look At Recent Price Target Changes By The Most Accurate Analysts ↗

November 14, 2023

Alcon Inc. (NYSE: ALC) is projected to release financial results for its third quarter, after the closing bell on Nov. 14, 2023.

Via Benzinga

Alcon Showcases Cloud-based Planning and World-class Digital Technologies During AAO 2023

October 30, 2023

From Alcon Inc. Investors

Via Business Wire

Alcon Launches TOTAL30 Multifocal Contact Lenses for Patients with Presbyopia

October 10, 2023

From Alcon Inc. Investors

Via Business Wire

Cataract Surgery with Alcon’s AcrySof IQ Vivity IOLs Demonstrates Sustained High Patient Satisfaction and Reduced Spectacle Dependence

September 09, 2023

From Alcon Inc. Corporate

Via Business Wire

Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030

September 08, 2023

EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(OTCQX:RHHBY) EQNX::TICKER_END

Via FinancialNewsMedia

Alcon Announces its Largest-Ever Scientific Program at the 41st Congress of the ESCRS, Showcasing New Data and Innovation to Support Ophthalmic Surgical Teams

September 06, 2023

From Alcon Inc. Corporate

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For August 17, 2023 ↗

August 17, 2023

Via Benzinga

NVIDIA To Rally Around 84%? Here Are 10 Other Analyst Forecasts For Thursday ↗

August 17, 2023

BMO Capital lowered the price target for Target Corporation (NYSE: TGT) from $140 to $130. BMO Capital analyst Kelly Bania maintained a Market Perform rating. Target shares gained 0.3% to $129.10 in...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.